The DUSP14 Knockout HeLa Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population in which the DUSP14 gene has been disrupted, enabling loss-of-function studies of this dual-specificity phosphatase in a human epithelial carcinoma model. This genetically heterogeneous pool of knockout cells avoids clonal selection biases and is well-suited for investigating DUSP14-dependent signaling mechanisms and cellular responses across a range of experimental contexts.
These knockout cells are derived from the HeLa cell line, an immortalized human epithelial line originally isolated from an HPV18-positive cervical adenocarcinoma. HeLa cells exhibit a hypertriploid karyotype and constitutively express the viral oncoproteins E6 and E7, which deregulate p53 and Rb tumor suppressor pathways, respectively. The resulting transformed phenotype features robust proliferation, altered apoptosis thresholds, and extensive rewiring of stress and growth factor signaling networks, making HeLa a widely adopted system for cancer biology, signal transduction, and drug development studies.
DUSP14 encodes a dual-specificity phosphatase that catalyzes the dephosphorylation of the mitogen-activated protein kinases (MAPKs) ERK, JNK, and p38, thereby attenuating downstream phosphorylation cascades. Its expression is induced by inflammatory cytokines and growth factors such as TNF-??, IL-1??, EGF, and PDGF, as well as by T-cell receptor (TCR) activation and oxidative stress, forming a negative feedback loop. Mechanistically, DUSP14 interacts directly with ERK2, JNK1, and p38??, and is recruited to signaling complexes containing adaptor proteins TRAF2 and TAB1 and the innate immune sensor NOD2. By restricting the activity of transcription factors including c-Jun, ATF2, and Elk-1, DUSP14 modulates gene expression programs governing proliferation, differentiation, immune responses, and survival.
In the HeLa background, where MAPK cascades are constitutively active due to viral oncoprotein expression and autocrine growth factor loops, DUSP14 knockout allows rigorous dissection of its regulatory role in cancer-relevant processes. The polyclonal knockout population can be used to assess changes in basal and stimulated ERK, JNK, and p38 phosphorylation, revealing the impact on downstream effectors such as MAPKAPK2, MSK1, and RSK. Because HeLa cells retain functional NOD-like receptor pathways, this model also enables investigation of DUSP14??s involvement in NOD2-RIPK2-TAK1-NF-??B signaling, bridging MAPK regulation and innate immunity within an epithelial tumor context.
Typical applications include biochemical analysis of MAPK phosphorylation kinetics via Western blotting and phospho-specific ELISA, transcriptional profiling of AP-1 and NF-??B target genes by RT-qPCR or luciferase reporter assays, and functional studies using migration, invasion, and drug sensitivity assays. Co-immunoprecipitation and phosphatase activity assays can be employed to characterize DUSP14 substrate specificity and interactome dynamics. The polyclonal format also facilitates high-throughput screening for small-molecule modulators of phosphatase activity or synthetic lethal interactions. For additional details or technical support, please contact Ascent Research.
